EML4 and non-small cell lung carcinoma: <h4>Objective</h4>This study aimed to investigate prognostic factors and establish prognostic models for EML4-ALK-positive non-small cell lung cancer (NSCLC) patients receiving ALK tyrosine kinase inhibitors (TKIs) treatment.<h4>Methods</h4>We retrospectively analyzed 114 ALK-positive NSCLC patients treated at our institution from January 2020 to January 2024.